We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 401

Supreme Court Hears Oral Argument On Constitutionality Of Inter Partes Review In Oil States
  • Fitzpatrick, Cella, Harper & Scinto
  • USA
  • November 28 2017

On November 27, 2017, the Supreme Court heard oral argument in Oil States Energy Services, LLC v. Greene's Energy Group, LLC, No. 16-712. The Supreme


Two bites of the apple: five facts about drug patent inter partes review final written decisions
  • Fitzpatrick, Cella, Harper & Scinto
  • USA
  • November 20 2017

As of July 20 2017 there had been at least 363 inter partes review petitions filed against patents that were listed in the Food and Drug


Federal Circuit Holds That TC Heartland Was A “Change of Law”
  • Fitzpatrick, Cella, Harper & Scinto
  • USA
  • November 16 2017

On November 15, 2017, Federal Circuit Judges Taranto, Chen, and Hughes in In re Micron Technology, Inc. (Appeal No. 2017-138) held that TC Heartland


Pharma at Patent Trial and Appeal Board
  • Fitzpatrick, Cella, Harper & Scinto
  • USA
  • November 6 2017

There has been some concern regarding the statistics periodically issued by the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark


Divided Federal Circuit holds that petitioner must prove all propositions of unpatentability
  • Fitzpatrick, Cella, Harper & Scinto
  • USA
  • October 30 2017

On October 4 2017 a divided en banc Federal Circuit issued several opinions addressing the burden of proof concerning a motion to amend claims in


Amgen obtains $70 million damages award against Hospira for erythropoietin patent infringement
  • Fitzpatrick, Cella, Harper & Scinto
  • USA
  • October 23 2017

On September 22 2017 a District of Delaware jury in Amgen v Hospira (15-cv-839-RGA (D Del)) awarded Amgen $70 million for Hospira's infringement of


Determining 'regular and established place of business' under patent venue statute
  • Fitzpatrick, Cella, Harper & Scinto
  • USA
  • October 16 2017

On September 21 2017 a Federal Circuit panel rejected an Eastern District of Texas judge's proposed four-factor test for determining whether venue


In re Aqua Products: In a Divided Decision, En Banc Federal Circuit Holds That Petitioner Must Prove All Propositions of Unpatentability, Including for Amended Claims
  • Fitzpatrick, Cella, Harper & Scinto
  • USA
  • October 5 2017

On October 4, 2017, a divided en banc Federal Circuit issued several opinions addressing the burden of proof pertaining to a motion to amend claims in


Amgen Obtains $70 Million Damages Award Against Hospira For Infringement Of Amgen’s Erythropoetin Patent
  • Fitzpatrick, Cella, Harper & Scinto
  • USA
  • September 27 2017

On September 22, 2017, a District of Delaware jury in the matter Amgen v. Hospira, 15-cv-839-RGA (D. Del.) returned a verdict awarding Amgen $70


“Regular And Established Place Of Business” Under Patent Venue Statute
  • Fitzpatrick, Cella, Harper & Scinto
  • USA
  • September 25 2017

On September 21, 2017, a Federal Circuit panel rejected an Eastern District of Texas judge's proposed four-factor test for determining whether venue